Neuromodulation + Neurorehabilitation for Concussion + PTSD
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a combination treatment for individuals experiencing attention issues after a mild traumatic brain injury (mTBI), with or without PTSD. It combines computer-based attention training (APT) and magnetic stimulation (iTBS, or Intermittent Theta Burst Stimulation) to evaluate their effectiveness in improving attention problems. Participants will join one of four groups, each testing different combinations of these treatments to determine the most effective approach. Eligible participants have experienced mTBI for at least three months and face attention challenges in daily life. As an unphased trial, this study provides a unique opportunity to contribute to innovative research that could enhance attention treatments for mTBI patients.
Will I have to stop taking my current medications?
The trial requires that you stop taking certain medications, such as CNS stimulants, during participation. If your mental health medication dosage has changed in the last 30 days, you may not be eligible. Please consult with the trial team for specific guidance on your medications.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that Attention Process Training (APT) is safe and well-tolerated. It improves attention skills after brain injuries, such as concussions, without causing significant side effects.
Intermittent theta burst stimulation (iTBS) is also safe. It effectively treats conditions like PTSD and depression by using short magnetic pulses to stimulate the brain. Studies report no major safety concerns, and participants usually handle the treatment well.
Both APT and iTBS have strong safety records. For those considering joining a trial, these treatments have been studied and found to be safe.12345Why are researchers excited about this trial's treatments?
Researchers are excited about these treatments because they combine neuromodulation and cognitive training to tackle concussion and PTSD in a new way. Unlike standard treatments that often focus on medication or traditional therapy, this approach uses intermittent theta-burst stimulation (iTBS) targeting the brain's dorsolateral prefrontal cortex, potentially enhancing brain plasticity and cognitive function. Additionally, the Attention Process Training (APT) program offers a novel computer-based cognitive training experience. Together, these treatments could offer faster and more effective relief from symptoms by directly engaging and retraining the brain's pathways.
What evidence suggests that this trial's treatments could be effective for concussion and PTSD?
Research has shown that both APT (Attention Process Training) and iTBS (intermittent theta-burst stimulation) hold promise for alleviating symptoms of mild traumatic brain injury (mTBI) and PTSD (post-traumatic stress disorder). APT has successfully improved attention and cognitive skills in individuals with brain injuries, regardless of the injury's severity or timing. iTBS, meanwhile, quickly alleviates PTSD symptoms and has demonstrated positive effects on depression. In this trial, participants will be assigned to different treatment arms to evaluate these therapies' effects. Some will receive real APT combined with real iTBS, while others will receive placebo versions of one or both treatments. Early evidence suggests that combining these therapies could significantly enhance attention and cognitive skills.36789
Who Is on the Research Team?
Theresa LB Pape, Dr.PH
Principal Investigator
Northwestern University
Are You a Good Fit for This Trial?
This trial is for adults aged 18-60 who have experienced a mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) between 3 months to 10 years ago. Candidates must be fluent in English, not involved in other studies, without epilepsy or severe heart conditions, not pregnant, and free from certain metal implants that affect MRI or TMS procedures.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo 30 1-hour treatment sessions of APT and iTBS, conducted 3 times per week for 10 weeks
Follow-up
Participants are monitored for changes in PTSD symptoms and adaptability using PCL and MPAI assessments
What Are the Treatments Tested in This Trial?
Interventions
- APT
- iTBS
Find a Clinic Near You
Who Is Running the Clinical Trial?
Northwestern University
Lead Sponsor
Theresa Pape
Lead Sponsor